Eliem Provides Update on ETX-810 and ETX-155 Clinical Programs
25 avr. 2022 07h00 HE
|
Eliem Therapeutics, Inc.
Phase 2a clinical trial of ETX-810 in diabetic peripheral neuropathic pain (DPNP) did not achieve the primary endpoint Phase 2a clinical trial evaluating ETX-810 in patients with lumbosacral...
Eliem Therapeutics Appoints Susan Franks as Senior Vice President and Head of Regulatory Affairs
05 avr. 2022 07h00 HE
|
Eliem Therapeutics, Inc.
SEATTLE and CAMBRIDGE, United Kingdom, April 05, 2022 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (Nasdaq: ELYM), a clinical-stage biotechnology company focused on developing novel therapies for...
Eliem Therapeutics to Present at Stifel’s 2022 CNS Days
21 mars 2022 07h00 HE
|
Eliem Therapeutics, Inc.
SEATTLE and CAMBRIDGE, United Kingdom, March 21, 2022 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (Nasdaq: ELYM), a clinical-stage biotechnology company focused on developing novel therapies for...
Eliem Therapeutics Reports Fourth Quarter and Year-End Financial and Business Highlights
07 mars 2022 16h10 HE
|
Eliem Therapeutics, Inc.
Completed dosing in Phase 2a clinical trial of ETX-810 in subjects with diabetic peripheral neuropathic pain; topline data to be presented in 1H 2022 Interim data from Phase 1b clinical trial of...
Eliem Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference
11 févr. 2022 07h00 HE
|
Eliem Therapeutics, Inc.
SEATTLE and CAMBRIDGE, United Kingdom, Feb. 11, 2022 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (Nasdaq: ELYM), a clinical-stage biotechnology company focused on developing novel therapies for...
Eliem Therapeutics Host Virtual Investor Event Featuring Opinion Leaders in Chronic Pain Research on February 16, 2022
07 févr. 2022 07h00 HE
|
Eliem Therapeutics, Inc.
SEATTLE and CAMBRIDGE, United Kingdom, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (Nasdaq: ELYM), a clinical-stage biotechnology company focused on developing novel therapies for...
Eliem Therapeutics Provides Program Updates and an Overview of Expected Near-Term Milestones
18 janv. 2022 07h00 HE
|
Eliem Therapeutics, Inc.
ETX-810 Phase 2a trial in diabetic peripheral neuropathic pain (DPNP) is fully enrolled Investigational New Drug (IND) application planned in Q1 2022 for ETX-155 Phase 2 trials in major depressive...
Eliem Therapeutics Reports Third Quarter Financial and Business Highlights
08 nov. 2021 16h01 HE
|
Eliem Therapeutics, Inc.
Advanced ETX-155 clinical development program, with the first subject successfully screened in epilepsy proof-of-concept trial and significant progress made toward the initiation of major depressive...
Eliem Therapeutics to Participate at Four Upcoming Investor Conferences
04 nov. 2021 07h00 HE
|
Eliem Therapeutics, Inc.
SEATTLE and CAMBRIDGE, United Kingdom, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc., a clinical-stage biotechnology company focused on developing novel therapies for neuronal...
Eliem Therapeutics Reports Second Quarter Financial Results
13 sept. 2021 16h10 HE
|
Eliem Therapeutics, Inc.
On track to advance two clinical programs through five proof-of-concept trials and progress two preclinical programs over the next 18-24 months Recently completed an IPO for $92 million in gross...